Hotline:
+ 49 (0) 2204 2918806

Market studies for category Healthcare

Items 1 to 10 of 70 total

  1. 1
  2. | 2
  3. | 3
  4. | 4
  5. | 5
  6. | 6
  7. | 7
  1. Net price*
    Year
  2. $6,995.00
    2012
    Für diese Studie liegt keine Bewertung vor.

    Custirsen Sodium (Prostate Cancer) - Forecast and Market Analysis to 2022

    GlobalData
    55 pages
    Introduction GlobalData has released its new PharmaPoint Drug Evaluation report, “Custirsen Sodium (Prostate Cancer) - Forecast and Market Analysis to 2022”. The recent approvals of second-line metastatic castration-resistant prostate cancer (mCRPC) therapies like J&J’s Zytiga (abiraterone acetate) and Medivation/Astellas’ Xtandi
    Englisch | Report | SKU: 330292
  3. $2,500.00
    2012
    Für diese Studie liegt keine Bewertung vor.

    Pancreatic Cancer Global Clinical Trials Review, H2, 2012

    GlobalData
    131 pages
    Introduction GlobalData's clinical trial report, “Pancreatic Cancer Global Clinical Trials Review, H2, 2012" provides data on the Pancreatic Cancer clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Pancreatic Cancer. It includes an overview of the trial numbers and their recr
    Englisch | Report | SKU: 329567
  4. $1,000.00
    2012
    Für diese Studie liegt keine Bewertung vor.

    64th American Academy of Neurology, 2012 - Post-conference Review and Analysis

    GlobalData
    20 pages
    Introduction GlobalData, the industry analysis specialist, has released its new conference alerts, “64th American Academy of Neurology, 2012 - Post-conference Review and Analysis”. The conference alert is an essential source of information and analysis on the emerging therapies and new disease management techniques.The annual symposiu
    Englisch | Report | SKU: 325431
  5. $6,995.00
    2012
    Für diese Studie liegt keine Bewertung vor.

    Tasquinimod (Prostate Cancer) - Forecast and Market Analysis to 2022

    GlobalData
    56 pages
    Introduction GlobalData has released its new PharmaPoint Drug Evaluation report, “Tasquinimod (Prostate Cancer) - Forecast and Market Analysis to 2022”. The recent approvals of second-line metastatic castration-resistant prostate cancer (mCRPC) therapies like J&J’s Zytiga (abiraterone acetate) and Medivation/Astellas’ Xtandi (enza
    Englisch | Report | SKU: 330299
  6. $2,500.00
    2012
    Für diese Studie liegt keine Bewertung vor.

    Non-Hodgkin Lymphoma Global Clinical Trials Review, H2, 2012

    GlobalData
    160 pages
    Introduction GlobalData's clinical trial report, “Non-Hodgkin Lymphoma Global Clinical Trials Review, H2, 2012" provides data on the Non-Hodgkin Lymphoma clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Non-Hodgkin Lymphoma. It includes an overview of the trial numbers and t
    Englisch | Report | SKU: 329573
  7. $3,995.00
    2012
    Für diese Studie liegt keine Bewertung vor.

    EpiCast Report: Multiple Sclerosis - Epidemiology Forecast to 2022

    GlobalData
    56 pages
    Introduction Multiple sclerosis (MS) is an inflammatory disease in which the myelin sheaths around the axons of the brain and spinal cord are damaged, leading to demyelination and a wide range of signs and symptoms. MS affects 2.5 million people worldwide each year and is the most debilitating neurological disease in young adults (Fernan
    Englisch | Report | SKU: 330208
  8. $2,500.00
    2012
    Für diese Studie liegt keine Bewertung vor.

    Esophageal Cancer Global Clinical Trials Review, H2, 2012

    GlobalData
    107 pages
    Introduction GlobalData's clinical trial report, “Esophageal Cancer Global Clinical Trials Review, H2, 2012" provides data on the Esophageal Cancer clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Esophageal Cancer. It includes an overview of the trial numbers and their recr
    Englisch | Report | SKU: 325436
  9. $2,995.00
    2012
    Für diese Studie liegt keine Bewertung vor.

    PharmaPoint: Prostate Cancer - Current and Future Players

    GlobalData
    57 pages
    Introduction GlobalData has released its pharma report, “PharmaPoint: Prostate Cancer - Current and Future Players”. The report is a vital source of up-to-date information with in-depth analysis on the companies in the rapidly growing Prostate Cancer Market. The report identifies and analyses the key companies shaping and driving the
    Englisch | Report | SKU: 330439
  10. $4,995.00
    2012
    Für diese Studie liegt keine Bewertung vor.

    PharmaPoint: Prostate Cancer - Italy Drug Forecast and Market Analysis to 2022

    GlobalData
    165 pages
    Introduction GlobalData has released its new Country report, “PharmaPoint: Prostate Cancer - Italy Drug Forecast and Market Analysis to 2022”. The recent approvals of second-line metastatic castration-resistant prostate cancer (mCRPC) therapies like J&J’s Zytiga (abiraterone acetate) and Medivation/Astellas’ Xtandi (enzalutamide)
    Englisch | Report | SKU: 330261
  11. $2,500.00
    2012
    Für diese Studie liegt keine Bewertung vor.

    Vaginal Cancer Global Clinical Trials Review, H2, 2012

    GlobalData
    81 pages
    Introduction GlobalData's clinical trial report, “Vaginal Cancer Global Clinical Trials Review, H2, 2012" provides data on the Vaginal Cancer clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Vaginal Cancer. It includes an overview of the trial numbers and their recruitment s
    Englisch | Report | SKU: 325441

Items 1 to 10 of 70 total

  1. 1
  2. | 2
  3. | 3
  4. | 4
  5. | 5
  6. | 6
  7. | 7